January 20, 2023
The attorneys who represented investors in a class action against a New Jersey pharmaceutical company have won a $1.33 million fee award for the suit, which was based on allegedly broken promises the company made about how it would present new information about a drug.
April 15, 2022
A biopharmaceutical company acquired by Gilead Sciences will pay $4 million to resolve class claims in New Jersey federal court alleging it misled investors into expecting that new drug results would be presented at conferences of the American Society of Clinical Oncology, according to a motion seeking preliminary approval of the deal.
June 01, 2020
A New Jersey federal judge on Monday refused to toss a proposed class action against Immunomedics Inc. after concluding that a shareholder had improved his complaint alleging the biopharmaceutical company misled investors into expecting it would present new drug results at upcoming conferences of the American Society of Clinical Oncology.
April 01, 2019
Immunomedics Inc. has at least temporarily dodged a stock-drop suit accusing it of hyping investors on its planned presentation at the 2016 American Society of Clinical Oncology's annual meeting only for the company's event to be canceled.
June 10, 2016
An investor for clinical-stage biopharmaceutical company Immunomedics Inc. on Thursday filed a putative class action against the company, alleging that misstatements about its eligibility to present research about trials for a breast and lung cancer treatment at a conference led to a drop in stock prices.